DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX� in Healthy Subjects

Information source: Optinose US Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Migraine

Intervention: Sumatriptan (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Optinose US Inc.


The purpose of this study is:

- To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg

OPTINOSE SUMATRIPTAN with 20 mg IMITREX (sumatriptan) Nasal Spray, 100 mg IMITREX (sumatriptan) Oral Tablet, and 6 mg IMITREX (sumatriptan) Subcutaneous Injection, in healthy subjects.

- To estimate the relative bioavailability of single-dose intranasal administration of 20

mg OPTINOSE SUMATRIPTAN, 20 mg IMITREX (sumatriptan) Nasal Spray, and 100 mg IMITREX (sumatriptan) Oral Tablet compared to a single-dose of 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.

Clinical Details

Official title: An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX (Sumatriptan) Nasal Spray, 100 mg IMITREX (Sumatriptan) Oral Tablet and 6 mg IMITREX (Sumatriptan) Subcutaneous Injection in Healthy Subjects

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

The pharmacokinetic parameters of sumatriptan following the administration of OPTINOSE SUMATRIPTAN and IMITREX® (sumatriptan).

Bioavailability of sumatriptan following the administration of OPTINOSE SUMATRIPTAN and IMITREX® (sumatriptan).

Secondary outcome:

Sensory attributes of the intranasal OPTINOSE SUMATRIPTAN product and IMITREX® (sumatriptan).

Safety Evaluations of the intranasal OPTINOSE SUMATRIPTAN product and IMITREX®


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Men or women ages 18 to 55 years, inclusive, at screening.

- Healthy with no clinically relevant abnormalities in the opinion of the Investigator

as determined by medical history, physical examination, blood chemistry, hematology, including complete blood count, urinalysis, vital signs, and ECG.

- Have a BMI of 18-32 kg/m2, inclusive, and a body weight of not less than 50 kg.

- For females of childbearing potential: either be sexually inactive (abstinent) for 14

days prior to the first dose and throughout the study or be using one of the following acceptable birth control methods:

- intrauterine device in place for at least 3 months prior to the first dose and

throughout the study.

- barrier methods (condom, diaphragm) with spermicide for at least 14 days prior

to the first dose and throughout the study.

- surgical sterilization of the partner (vasectomy for 6 months minimum).

- hormonal contraceptives for at least 3 months prior to the first dose of the

study and throughout the study.

- Female subjects who claim to be sexually inactive, but become sexually active

during the course of the study must agree to use a barrier method (e. g. condom, diaphragm) with spermicide from the time of the start of sexual activity through completion of the study.

- In addition, female subjects of childbearing potential will be advised to remain

sexually inactive or to keep the same birth control method for the whole duration of the study.

- Females of non-childbearing potential must have undergone one of the following

sterilization procedures at least 6 months prior to Day 1:

- bilateral tubal ligation

- hysterectomy

- bilateral oophorectomy or be postmenopausal with amenorrhea for at least 1 year

prior to Day 1 and follicle stimulating hormone (FSH) serum levels ≥ 40 mIU/mL.

- Women of child-bearing potential must have a negative serum beta-human chorionic

gonadotropin at the screening visit and at each check-in prior to dosing.

- Agree to abstain from alcohol intake 48 hours before each administration of study

agent and during inpatient portion of the study.

- Agree to limit caffeine/methylxanthine (eg, coffee, tea, chocolate, or

caffeine-containing soft drinks) intake to less than 300 mg/day for 7 days prior to and for the duration of the study (300 mg of caffeine is equal to approximately 3 cups of coffee or 6 cola drinks), with no intake from 24 hours before dosing and throughout confinement.

- Agree not to consume food or beverages containing, grapefruit or grapefruit juice,

Seville oranges, or quinine (e. g. tonic water) 72 hours prior to study Day - 1 until

after the last PK sample is collected.

- Agree not to consume food containing poppy seeds during the study.

- Have verified airflow through both nostrils and an ability to close the soft palate.

- Must be able to use the OptiNose device correctly.

- Subjects must understand English and have signed an informed consent document

indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

- Be willing to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

- Currently have or have a history of disease or dysfunction of the pulmonary,

cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, or other body system that is clinically significant in the opinion of the Investigator.

- Have evidence of any chronic medical conditions requiring prescription medications

(eg, hypertension or diabetes).

- Have a history of migraines.

- History of hypersensitivity or allergies to any drug compound, including sumatriptan,

any of its components or sulphonamides.

- Have had a major or traumatic surgery within 12 weeks prior to screening, pre-planned

surgery or procedures that would interfere with the conduct of the study.

- Have an acute illness within 7 days prior to study agent administration or have had a

major illness or hospitalization within 1 month prior to study agent administration.

- Have clinically significant findings on screening ECG.

- Have a recent history (within 1 previous year) of alcohol or drug abuse.

- History of smoking or use of nicotine-containing substances within the previous 2


- Have abnormal values for hematology, clinical chemistry, or urinalysis at screening

or check-in considered clinically significant by the Investigator.

- Have a positive serology test for HIV antibodies, HBsAg, or hepatitis C virus

antibody (anti-HCV) at screening.

- Have a positive urine drug screen for ethanol or substances of abuse including

cocaine, cannabinoids, phencyclidine, amphetamines, benzodiazepines, barbiturates, opiates, propoxyphene, and methadone at screening and each check-in.

- Have a haemoglobin level below the lower limit of normal at screening.

- Have donated blood or experienced significant blood loss (volume > 500 mL) within 3

months prior to screening, or is planning to donate within 2 months after completion of the study.

- Use of drug metabolizing enzyme (CYP-450) inducers within 28 days prior to dosing or

inhibitors within 14 days prior to dosing (refer to Appendix 1).

- Use of any monoamine oxidase inhibitors (MAOI) within 28 days prior to dosing.

- Use of any prescription medications/products, except hormonal contraceptives, within

14 days prior to study entry.

- Use of any OTC, nonprescription preparation (including minerals and

phytotherapeutic/herbal/plant-derived preparations), within 14 days prior to study entry, with the exception of ibuprofen, and acetaminophen used at recommended doses. For acetaminophen, a maximum of 1500 mg per day and no more than 3 g per week, will be allowed for the treatment of headache or other pain.

- Participation in any other investigational study drug trial in which receipt of an

investigational study drug occurred within 4 weeks prior to dosing, or plan to participate in an investigational drug study less than 1 month after completion of the study.

- A recent febrile illness within 3 days of the start of the study drug intake on Day


- If a woman, must not be breast-feeding or planning to become pregnant during the


- Must refrain from physical activity (jogging, strenuous exercise of all types), and

sunbathing while confined to the study center and 48 hours before admission to the study center.

- Reports or exhibits abnormalities regarding the sense of smell and/or taste.

- Reports a temporary loss of or abnormality of sense of smell and/or taste due to

recent (within the 2 weeks prior to Day 1) cold or viral infections.

- Presence of respiratory diseases or known nasal obstruction including allergic

rhinitis, nasal septum deviation, polyposis, severe mucosal swelling, nasal ulcers, nasal trauma,or any other reason.

- Have a history of chronic nose bleeds.

- Current nasopharyngeal illness.

- Known velum insufficiency, ie, those with cleft palate and/or structural

abnormalities in the soft palate and nasopharynx.

- Any condition that in the opinion of the Investigator would complicate or compromise

the study, or the well-being of the subject.

- Is an employee of the Investigator/study center or the Sponsor.

Locations and Contacts

Celerion, Neptune, New Jersey 07753, United States
Additional Information

Starting date: January 2012
Last updated: February 28, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017